Core Insights - Sight Sciences, Inc. is an eyecare technology company focused on developing innovative interventional technologies to transform care and improve patients' lives [1][3] - The company will present at the 25th Annual Needham Healthcare Conference on April 13, 2026, at 11:15 am PT / 2:15 pm ET, with a live and archived webcast available [2] Company Overview - Sight Sciences specializes in minimally invasive or non-invasive solutions targeting prevalent eye diseases, aiming to enhance patient care and replace outdated treatment methods [3] - The company's key products include the OMNI® Surgical System and OMNI® Edge Surgical System, which are implant-free technologies for glaucoma surgery, indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma [3] - The OMNI Surgical System is CE Marked for specific procedures related to glaucoma treatment, while the SION® Surgical System is a bladeless device for excising trabecular meshwork [3] - The TearCare® System is 510(k) cleared in the U.S. for localized heat therapy in adult patients with evaporative dry eye disease, addressing meibomian gland disease [3]

Core Viewpoint - The U.S. District Court for the District of Delaware upheld the jury's finding of willful infringement by Alcon and awarded Sight Sciences over $34 million in past damages, along with ongoing royalties through November 2028 [1][2]. Legal Outcome - The Court's order confirmed the jury's verdict that Alcon willfully infringed all three of Sight Sciences' asserted patents and awarded $34 million in monetary damages, which includes $5.5 million in lost profits and $28.5 million in royalty damages [2][6]. - An ongoing royalty of 10% of Hydrus revenue will be applicable until the expiration of Sight Sciences' last asserted patent on November 10, 2028 [2][6]. Company Perspective - Sight Sciences expressed satisfaction with the ruling, emphasizing the importance of its intellectual property portfolio in interventional glaucoma and its commitment to advancing glaucoma care through innovative technologies [4]. - The company anticipates recording a $5.4 million success fee related to the litigation, which will be excluded from non-GAAP adjusted operating expenses [4]. Product and Technology Focus - Sight Sciences is dedicated to developing innovative and interventional solutions for eye care, particularly in the field of glaucoma, utilizing minimally invasive techniques [5]. - The company's products include the OMNI® Surgical System and OMNI® Edge Surgical System, which are designed to reduce intraocular pressure in patients with primary open-angle glaucoma [5].

Core Viewpoint - Sight Sciences, Inc. has achieved a significant legal victory in its patent infringement case against Alcon, with the court upholding the jury's verdict of willful infringement and awarding substantial monetary damages [1][2]. Legal Outcome - The U.S. District Court for the District of Delaware confirmed the jury's verdict that Alcon willfully infringed three patents held by Sight Sciences, resulting in a monetary award of $34 million for past infringement, along with ongoing royalties of 10% of Hydrus revenue until November 10, 2028 [2][6]. - The final judgment is pending and will include supplemental damages and interest, with the possibility of an appeal by Alcon [2][6]. Financial Implications - The past monetary damages consist of $5.5 million in lost profits and $28.5 million in royalty damages related to Hydrus sales from its launch until the jury verdict [6]. - The company anticipates recording a $5.4 million success fee to operating expenses, which will be excluded from non-GAAP adjusted operating expenses [4]. Company Overview - Sight Sciences focuses on developing innovative eyecare technologies aimed at transforming patient care, particularly in the field of glaucoma treatment [5]. - The company's product offerings include the OMNI® Surgical System and TearCare® System, which utilize minimally invasive techniques to address prevalent eye diseases [5]. Intellectual Property Strategy - The company emphasizes the importance of safeguarding its intellectual property portfolio, which includes microinvasive glaucoma implants and canaloplasty devices, to support ongoing innovation and investment in new treatment solutions [4].

Core Insights - The company achieved a significant reimbursement milestone in Q4 with the establishment of pricing for CPT code 0563T related to the TearCare procedure, marking a turning point in its strategy to lead the reimbursed interventional dry eye treatment market [1] - The business segments have been redefined from "surgical glaucoma" and "dry eye" to "interventional glaucoma" and "interventional dry eye," reflecting a focus on earlier procedure-based interventions [2] Financial Performance - In Q4 2025, total revenue was $20.4 million, representing a 7% year-over-year increase, with adjusted operating expenses down 23% to $18.9 million and a net loss narrowed to $4.2 million [3][13] - Interventional glaucoma revenue was $19.7 million, up 5% year-over-year, while interventional dry eye revenue was $0.7 million, showing growth from $0.3 million in the prior year [4][5] - The company has provided 2026 revenue guidance of $82 million to $88 million, indicating a growth of 6% to 14% compared to 2025 [11] Strategic Focus - Management is emphasizing operational discipline and cash management, with a cash position of $92 million at the end of Q4 [3][13] - The company is targeting high-volume dry eye prescribers and engaging new providers in states with established fee schedules, leveraging existing glaucoma customers for TearCare adoption [6] - An "interventional glaucoma evaluation workflow" is being developed to enhance standalone adoption in the glaucoma market [9][10] Market Dynamics - The interventional glaucoma segment is expected to grow low single digits in Q1 2026, with a stronger performance anticipated in the second half of the year [11] - The company is focusing on expanding the standalone glaucoma market and investing in targeted commercial resources [9]

Core Insights - Sight Sciences, Inc. reported a solid fourth quarter with a return to growth in Interventional Glaucoma and encouraging traction in Interventional Dry Eye, emphasizing the strength of its technologies and infrastructure in the eye care market [3][4]. Financial Highlights - Fourth quarter 2025 revenue was $20.4 million, a 7% increase year-over-year, with Interventional Glaucoma revenue at $19.7 million (up 5%) and Interventional Dry Eye revenue at $0.7 million (up from $0.3 million) [4][8]. - Gross profit for Q4 2025 was $17.8 million, with a gross margin of 87%, consistent with the prior year [5][10]. - Total operating expenses decreased by 25% to $21.5 million in Q4 2025, driven by lower personnel-related expenses and stock-based compensation [6][11]. - The net loss for Q4 2025 was $4.2 million, or $0.08 per share, compared to a net loss of $11.8 million, or $0.23 per share, in the same period the previous year [7][12]. Full Year 2025 Results - Total revenue for 2025 was $77.4 million, a 3% decrease from 2024, with Interventional Glaucoma revenue flat at $75.7 million and Interventional Dry Eye revenue dropping to $1.6 million from $4.0 million [8][9]. - Gross margin for the full year was 86%, up from 85% in 2024, with Interventional Dry Eye gross margin increasing to 59% from 46% [10][11]. - Total operating expenses for 2025 were $103.8 million, a 13% decrease from 2024, with significant reductions in research and development and selling, general, and administrative expenses [11][12]. - The net loss for 2025 was $38.4 million, or $0.74 per share, an improvement from a loss of $51.5 million, or $1.03 per share, in 2024 [12][13]. 2026 Financial Guidance - The company expects 2026 revenue to range from $82 million to $88 million, representing growth of 6% to 14% compared to 2025, with Interventional Glaucoma revenue projected at $77 million to $81 million and Interventional Dry Eye revenue at $5 million to $7 million [14][15]. - Adjusted operating expenses for 2026 are anticipated to be between $93 million and $96 million, reflecting an increase of 6% to 9% due to targeted investments in both business segments [15].

Core Insights - Sight Sciences has appointed Alison Bauerlein as Chief Operating Officer and James Rodberg as Chief Financial Officer, effective November 5, 2025, to enhance its operational capabilities and drive growth in the interventional dry eye market [1][2] Leadership Appointments - The new appointments are aimed at strengthening the company's market leadership in minimally invasive glaucoma surgery (MIGS) and scaling the reimbursed interventional dry eye category [2] - Alison Bauerlein has a proven track record in leading high-growth medtech organizations and will focus on scaling the business [2][4] - James Rodberg brings a strong finance background and will support the company's growth and profitability goals [2][5] Board of Directors Update - Erica Rogers and Brenda Becker have stepped down from the Board of Directors, with acknowledgments of their contributions to the company's vision and mission [3] Company Overview - Sight Sciences is focused on developing innovative interventional solutions to improve patient care in eyecare, targeting prevalent eye diseases with minimally invasive approaches [7] - The company's products include the OMNI® Surgical System and TearCare® System, which address glaucoma and dry eye disease, respectively [7]

Core Viewpoint - Sight Sciences, Inc. is set to report its financial results for Q3 2025 on November 6, 2025, with a conference call scheduled to discuss the results [1]. Company Overview - Sight Sciences is an eyecare technology company focused on developing innovative interventional solutions aimed at transforming patient care and improving lives [3]. - The company utilizes minimally invasive or non-invasive methods to address prevalent eye diseases, aiming to enhance treatment paradigms and replace outdated approaches [3]. - Key products include the OMNI® Surgical System and OMNI® Edge Surgical System, which are implant-free technologies for glaucoma surgery, and the TearCare® System, which is designed for treating evaporative dry eye disease [3]. Upcoming Events - The financial results for the third quarter ending September 30, 2025, will be reported after market close on November 6, 2025 [1]. - A conference call to discuss these results will begin at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time [1]. - Investors can access a live and archived webcast of the conference call on the company's website [2].

Core Insights - Sight Sciences, Inc. announced that two Medicare Administrative Contractors (MACs), Novitas Solutions and First Coast Service Options, have established pricing for CPT code 0563T, which pertains to the TearCare® System for treating meibomian gland dysfunction [1][2][3] - The local fee schedule for CPT code 0563T will be effective for services on or after January 1, 2025, and will be available for eyecare providers in the respective jurisdictions [2][5] - The regions covered by Novitas and First Coast represent approximately 30% of total Medicare fee-for-service covered lives, amounting to an estimated 10.4 million covered lives [3][4] Company Developments - The CEO of Sight Sciences expressed gratitude for the established pricing, emphasizing the importance of access to the TearCare treatment for Medicare beneficiaries [1][5] - The company has launched the Sight Access Portal to assist providers with patient benefit verifications, prior authorizations, and reimbursement inquiries related to the TearCare System and other surgical systems [5][6] - Sight Sciences plans to provide updated revenue and adjusted operating expenses guidance during its third quarter 2025 earnings call [5] Industry Context - The TearCare® System is designed to address evaporative dry eye disease caused by meibomian gland disease, which is a prevalent condition affecting many patients [6][7] - The company focuses on developing innovative, minimally invasive technologies to improve patient care and transform treatment paradigms in eyecare [6][7]

Core Insights - Sight Sciences, Inc. is an eyecare technology company focused on developing innovative interventional technologies to improve patient care and transform treatment paradigms [1][3] - The company will present at the Morgan Stanley Global Healthcare Conference on September 10, 2025, at 10:50 am PT / 1:50 pm ET [2] Company Overview - Sight Sciences develops minimally invasive or non-invasive solutions targeting prevalent eye diseases, aiming to enhance patient care and replace outdated treatment methods [3] - The OMNI® Surgical System and OMNI® Edge Surgical System are implant-free technologies for glaucoma surgery, indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma [3] - The SION® Surgical System is a bladeless device for excising trabecular meshwork in ophthalmic procedures [3] - The TearCare® System is cleared for localized heat therapy in adult patients with evaporative dry eye disease, addressing meibomian gland disease [3]

Core Insights - Sight Sciences, Inc. will report its financial results for Q2 2025 on August 7, 2025, after market close [1] - A conference call to discuss the results will take place at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time [1] Company Overview - Sight Sciences is an eyecare technology company focused on innovative and interventional solutions to improve patient care [3] - The company develops minimally invasive or non-invasive technologies targeting prevalent eye diseases, aiming to enhance treatment paradigms [3] - Key products include the OMNI® Surgical System and OMNI® Edge Surgical System for glaucoma treatment, and the TearCare® System for evaporative dry eye disease [3]